Recent Updates
Recently added Catalysts
RCEL Negative Sentiment Score: 30/100

AVITA (RCEL) INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into AVITA Medical, Inc. and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is investigating AVITA Medical, Inc. (RCEL) for potential legal claims regarding violations of federal securities laws. This investigation was prompted by the company's report of a substantial backlog of unpaid provider claims for its Recell product, which has impacted financial performance and led to a significant drop in share price. The firm encourages affected investors to contact them for further information on their legal options.

Market Sentiment Analysis

CONCERNS & RISKS

  • Investigation into potential claims of federal securities law violations by AVITA.
  • Significant backlog of unpaid claims for Recell procedures, creating uncertainty for providers.
  • Share price decline of approximately 21% following adverse news.

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Avita (RCEL) To Contact Him Directly To Discuss Their Options
If you purchased or acquired stock in Avita and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Click here to participate in the action.
NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) --
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against AVITA Medical, Inc. (“Avita” or the “Company”) (NASDAQ:RCEL) on behalf of Avita stockholders. Our investigation concerns whether Avita has violated the federal securities laws and/or engaged in other unlawful business practices.
Investigation Details:
On August 7, 2025, Avita released its second quarter 2025 financial results, revealing “a six-month backlog in unpaid provider claims for Recell procedures impacted first-half demand.” The Company explained that contractors assigned by the Centers for Medicare & Medicaid Services to determine pricing of the Company’s wound care product, Recell, “neither assigned a price or assigned an inadequate price and failed to adjudicate claims in a timely manner.” As a result, “claims accumulated from January through June, creating a significant backlog of unpaid claims and inadequately paid claims to providers for Recell procedures. This lack of resolution created uncertainty among providers regarding payment expectations and timelines, which led to a reduction in Recell utilization during the first half of the year.”
On this news, the price of AVITA’s shares declined by $1.13 per share, or approximately 21%, from $5.38 per share on August 7, 2025 to close at $4.25 on August 8, 2025.
If you purchased or otherwise acquired Avita shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

How can I discuss my losses with Avita?

Contact Brandon Walker or Marion Passmore at Bragar Eagel & Squire by calling (212) 355-4648.

What is the reason for the investigation into Avita?

The investigation addresses potential violations of federal securities laws by Avita.

How did Avita's stock price change recently?

On August 7, 2025, Avita's shares fell by approximately 21% following financial results.

What were the findings from Avita's Q2 financial report?

The report showed a six-month backlog in unpaid provider claims for Recell procedures.

Is there a cost for discussing my claims with the firm?

No, there is no cost or obligation to discuss your claims with Bragar Eagel & Squire.

Last updated: Oct 3, 2025